Abstract
This study mainly focused on the impact of Hepatitis B virus (HBV) infection on the prognosis of diffuse large B cell lymphoma (DLBCL) patients in rituximab era, using a Cox regression model to ascertain the prediction value of the serum HBV marker in survivals. Three hundred and eighty four DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (R-CHOP-like regimens) or CHOP-like regimens were included. Progression-free survival (PFS) and overall survival (OS) of the patients have or have not received rituximab were analyzed separately. In the CHOP group, HBV infection has not been found a profound impact on the survivals. In the R-CHOP group, PFS and OS were inferior in HBsAg-positive patients (p=0.031 and p=0.006, respectively); after adjusting for International Prognostic Index parameters, HBsAg is an independent unfavorable factor for both PFS (RR=2.492) and OS (RR=2.589).
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
China
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Hepatitis B / complications*
-
Hepatitis B / pathology
-
Hepatitis B / virology
-
Hepatitis B Surface Antigens / metabolism*
-
Hepatitis B virus / genetics
-
Hepatitis B virus / isolation & purification
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / metabolism*
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Lymphoma, Large B-Cell, Diffuse / virology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Prednisone / administration & dosage
-
Prognosis
-
Retrospective Studies
-
Rituximab
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Hepatitis B Surface Antigens
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone